… As described, LGE cannot characterize and quantify diffuse myocardial disease or inform on
how non-contrasted areas are compensated for the increased workload or whether they are …

… of myocardial fibrosis with late gadolinium enhancement (LGE) by cardiovascular magnetic
resonance (… , non-contrast methods for detecting and monitoring myocardial fibrosis would be …

… ), as well as myocardial fibrosis. The purpose of … myocardial perfusion reserve (MPR) and
diffuse myocardial fibrosis in patients with HFpEF using cardiovascular magnetic resonance. A …

… after ST-segment elevation myocardial infarction (STEMI) remains around 10%. Cardiovascular
magnetic resonance imaging (CMR) … ECV can be used as a marker of diffuse fibrosis. …

… tissues will recover to its equilibrium with a rate determined … to detect diffuse myocardial
involvement, as myocardial … 2 mapping, however, measure intrinsic tissue properties, and …

… contrast (for instance, T2-weighted imaging as well as early and late gadolinium enhancement
(LGE) imaging) [41]. Therefore, more diffuse … to visualize diffuse myocardial disease has …

… of the myocardial changes on the basis of the intrinsic magnetic … in the early detection of
diffuse myocardial inflammation and fibrosis … -hold T1 quantification equilibrium contrast CMR. J …

… [26, 27], governed more by diffuse myocardial fibrosis measured by ECV than a disease …
versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn …

… On its removal, the protons return to equilibrium, releasing … In cardiac amyloidosis, global
diffuse enhancement is … . Myocardial perfusion cardiovascular magnetic resonance: optimized …

… imaging (CMR) allows for evaluation of myocardial … Cardiovascular magnetic resonance
(CMR) provides several of the … gadolinium contrast for T1 mapping sequences, the equilibrium …